In honor of #InternationalWomensDay, we’re celebrating the women leaders at Adverum who are shaping the future of biotech. From advancing gene therapy for #wetAMD to navigating the regulatory landscape and mentoring the next generation of scientists, their leadership and dedication inspire us every day. Swipe through to see what they had to say about mentorship, leadership, and the importance of empowering women in biotech. #IWD2025 #AccelerateAction #DiversityInSTEM #GeneTherapy #wAMD
Adverum Biotechnologies
生物技术研究
Redwood City，California 12,404 位关注者
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
关于我们
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
- 网站
-
https://www.adverum.com
Adverum Biotechnologies的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Redwood City，California
- 类型
- 上市公司
- 创立
- 2012
- 领域
- Gene Therapy、Biotechnology、Rare Diseases、Ophthalmology和Retina
地点
-
主要
获取路线
100 Cardinal Way
US，California，Redwood City，94063
Adverum Biotechnologies员工
动态
-
We had a great time?engaging with the scientific community at the 53rd Annual Aspen Retinal Detachment Society Meeting! Thank you to Dr. Donald D'Amico, Dr. R.V. Paul Chan, and Tim Murray, MD MBA for hosting another outstanding event, and to Dr. Szilárd Kiss for his insightful presentation on Advances in Ocular Gene Therapy for Inherited and Multifactorial Retinal Disorders. A special thank you to Medical Conference Planners International for their flawless event coordination. ?
-
-
Don’t miss the fireside chat with Adverum’s management team today at the Cowen 45th Annual Healthcare Conference at 11:50 AM EST. Tune in live: https://bit.ly/4iq22VB A replay will be available on our website for at least 30 days following the event. #genetherapy #wAMD
-
-
Today, Adverum announced the initiation of ARTEMIS, our Phase 3 trial evaluating Ixo-vec for wet AMD. ARTEMIS is the first-ever registrational intravitreal gene therapy trial for this patient population—a significant milestone in advancing treatment options. Huge kudos to our team for their dedication and for consistently exceeding our ambitious timelines. Learn More: https://bit.ly/41pSFyj #ARTEMISTrial #GeneTherapy #wetAMD
-
Join us at the 53rd Annual Aspen Retinal Detachment Society Meeting! Don’t miss Adverum’s Board Director, Dr. Szilárd Kiss' presentation, Advances in Ocular Gene Therapy for Inherited and Multifactorial Retinal Disorders, on March 3 at 5:10 PM MT. Looking forward to connecting—see you there! #GeneTherapy #wAMD #ARDS2025
-
-
Be sure to catch Adverum presenting?at the 45th Annual TD Cowen Healthcare Conference Tuesday, March 4, at 11:50 a.m. ET. Tune in to the webcast here: https://bit.ly/4ewOCWq. A replay of the webcast will be available on the website for at least 30 days.
-
-
We’re thrilled to see Reed Tuckson, MD recognized in the latest issue of Board Prospects for his outstanding leadership and contributions to healthcare governance. As a valued Adverum Biotechnologies board member, Reed brings a wealth of experience, policy expertise, and a deep commitment to patient-centered care. Congratulations, Reed, on this well-deserved recognition! Read the full issue here: https://lnkd.in/g2YQTmD6
-
Congratulations?to Dr.?Arshad M. Khanani?on being awarded the Lawrence Singerman Medal by the Macula Society for “outstanding contributions to the advancement of science through retinal clinical trials.” Truly well-deserved recognition!
-
-
It’s been a busy and very productive month for us at Adverum. We attended several key ophthalmology meetings, including Angiogenesis, the Vail Vitrectomy meeting, the Telluride Retina Film Festival, and the Macula Society Annual Meeting. These gatherings provided invaluable opportunities to present company updates, connect with colleagues, and gain insights that will help shape our work throughout the year. #GeneTherapy #wetAMD
-
-
Our President & CEO Laurent Fischer is at Telluride Retina Film Festival with fellow Adverians and KOLs as we kick off AMD and Low Vision Awareness Month. Keep following us here this month as we highlight resources from key organizations and share updates as we move around the country for a busy month of conferences. Thanks to David Brown and Charles Wykoff for organizing an incredible, educational event!